Erasca, Inc. (ERAS): Capital Expenditures
$128.0K
Year ended 2025-12-31
$59.0K
Trailing 12 months to 2026-06-30
-79.4%
3-year compound annual growth
-33.0%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $128.0K | +113.3% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $60.0K | -96.6% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $1.77M | -87.8% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $14.55M | +29.9% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $11.21M | n/m | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $947.0K | n/a | 2022-03-24, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Erasca, Inc. (ERAS) | 2025-12-31 | $128.0K | +113.3% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $34.0K | -76.1% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $1.05M | +39.0% |
| Harrow, Inc. (HROW) | 2025-12-31 | $887.0K | -44.4% |
| Nkarta, Inc. (NKTX) | 2025-12-31 | $1.21M | -72.6% |
| MBX Biosciences, Inc. (MBX) | 2025-12-31 | $1.93M | +120.7% |
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $712.0K | -40.1% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $18.0K | -86.3% |
| Alumis Inc. (ALMS) | 2025-12-31 | $653.0K | -62.3% |
Compare ERAS, IRWD, TNGX, HROW side by side · Screen every company in Pharmaceutical Preparations ↗